What is EQUASHIELD?
Founded in 2009, EQUASHIELD operates at the intersection of robotics and clinical safety. The company specializes in the development of automated compounding robots and advanced closed system transfer devices (CSTDs). Its core value proposition lies in the rigorous protection of healthcare workers from hazardous drug exposure, a persistent challenge in oncology and pharmacy settings. By integrating sophisticated engineering with clinical workflows, EQUASHIELD has established itself as a leader in the niche but essential market of hazardous drug handling, ensuring that pharmaceutical preparation meets the highest standards of safety and efficiency.
How much funding has EQUASHIELD raised?
EQUASHIELD has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in EQUASHIELD
PPP
Public-Private Partnership
What's next for EQUASHIELD?
With this major enterprise-level funding, EQUASHIELD is poised to scale its operational footprint and enhance its R&D capabilities. The strategic allocation of this capital will likely focus on expanding the deployment of its automated compounding systems into new international markets and refining its existing CSTD product line. As healthcare systems increasingly prioritize worker safety and the reduction of manual errors in drug preparation, EQUASHIELD is strategically aligned to capture further market share. The company's trajectory suggests a shift toward broader integration within hospital pharmacy infrastructures, leveraging its technological moat to set new benchmarks for safety in the pharmaceutical supply chain.
See full EQUASHIELD company page
